Arcus Biosciences, Inc.
RCUS · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.26 | -0.16 | -1.83 |
| FCF Yield | -6.70% | -15.40% | -17.22% | -7.40% |
| EV / EBITDA | -10.06 | 181.16 | -5.93 | -14.33 |
| Quality | ||||
| ROIC | -18.88% | -0.90% | -12.50% | -11.12% |
| Gross Margin | 92.31% | 100.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.72 | – | 1.18 | 1.06 |
| Growth | ||||
| Revenue 3-Year CAGR | 26.11% | 29.49% | 5.92% | 32.20% |
| Free Cash Flow Growth | 27.07% | 0.00% | -31.68% | -504.00% |
| Safety | ||||
| Net Debt / EBITDA | 1.08 | -34.75 | 1.22 | 1.01 |
| Interest Coverage | -47.33 | -4.00 | -122.00 | -51.50 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -1,841.54 | 11.25 | 67.50 | 86.54 |